Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 52Vincristine 32blinatumomab 30Prednisone 27Methotrexate 27Cytarabine 25Dexamethasone 23Specimen Handling 21Rituximab 20Doxorubicin 19merphos 18Mercaptopurine 18Etoposide 18fludarabine 17Biopsy 17prednylidene 16deltacortene 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16Calcium Dobesilate 16dexamethasone acetate 15dexamethasone 21-phosphate 15auricularum 15Inotuzumab Ozogamicin 15pegaspargase 14azathiopurine 14venetoclax 13Asparaginase 13Spinal Puncture 12Leucovorin 12CT-P10 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × NKTR-255 × 1 year × Clear all
NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Stanford University

Phase 1 Active not recruiting
56 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡